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Abstract: Depending on the environmental conditions, cells adapt their metabolism and specific
growth rate. Rearrangements occur on many different levels such as macromolecular composition,
gene and protein expression, morphology and metabolic flux patterns. As the interplay of these
processes also determines the output of a recombinant protein producing system, having control
over specific growth rate of the culture is advantageous. Continuous culture methods were
developed to grow cells in a constant environment and have been used for decades to study basic
microbial physiology in a controlled and reproducible manner. Our review summarizes the uses of
continuous cultures in cell physiology studies and process development, with a focus on recombinant
protein-producing microorganisms.
Keywords: continuous cultures; continuous manufacturing; recombinant protein production; steady
state; specific growth rate; chemostat
1. Introduction
Efficient strategies to produce recombinant proteins are gaining increasing importance, as more
applications that require high amounts of high-quality proteins reach the market [1]. Higher production
efficiencies, faster process development and deeper understanding of basic cellular physiology are
required to advance the field. As recombinant protein production is built upon living organisms,
the process development is almost never straightforward and often demands an empirical approach.
To manipulate and understand cells better, they should be grown in a defined, ideally constant,
controllable set of physico-chemical conditions [2]. The most basic system that can provide such
conditions is a chemostat where cells are maintained in a steady-state growth environment by
supplying them with a constant flow of nutrients and by simultaneous removal of spent culture
medium at a defined rate [3,4]. Other parameters, such as temperature, pH, and oxygenation rate can
be varied and controlled by the experimenter. Several variations of the basic chemostat cultivation
method have been developed to study cells more rapidly while keeping the steady-state environment
(for a review of the methods see [5]). Most often, continuous cultures have been applied to basic
physiology studies of wild-type cells; but as the final volumetric productivity of a protein production
process depends both on the specific product formation rate (qp) and the specific growth rate (µ),
methods that allow the experimenter to control and monitor µ can also be advantageous for process
development purposes. Besides microbial physiology studies and process development, there is
an interest in continuous cultures to manufacture recombinant proteins [6,7], as the possibility of
Microorganisms 2018, 6, 56; doi:10.3390/microorganisms6030056 www.mdpi.com/journal/microorganisms
Microorganisms 2018, 6, 56 2 of 12
keeping cells in producing states for longer times has the potential to significantly increase the process
productivities and reduce costs [8,9].
In this review, we summarize how continuous cultures have been used to understand basics of
recombinant cell physiology, for process development and industrial production of recombinant
proteins. As semi-continuous perfusion processes have been used for mammalian cell-based
recombinant processes for a long time and reviewed elsewhere [10–12], our review focuses
on microorganisms.
2. Specific Growth Rate Dependent Metabolism of Microorganisms
Host cells can be considered as catalysts in the process of producing recombinant proteins. When
a genetic element designed to produce a protein of interest is placed into host cells, its output depends
strongly on the physiological state. One of the key characteristic of the physiological state of cells is
their specific growth rate (µ) [13]. Most changes in physico-chemical growth environment will have
an influence on the µ of cells. Additionally, for recombinant protein production it is common to use
strong expression systems that can also significantly burden host cells and influence µ.
Schaechter et al. first showed that the macromolecular composition (contents of ribonucleic
acid (RNA), DNA, and protein) of Salmonella typhimurium varies strongly according to how fast the
cells are growing [14]. This has been shown to apply also to many other microorganisms [15–17]. In
addition to macromolecular composition, all core parameters in the process of recombinant protein
production-plasmid copy number [18], transcription [19], and translation rate [20,21] are changing
with µ. Besides these general processes, recent genome-wide studies have shown that a large
fraction of the transcriptome, proteome, and fluxome in microorganisms seem to be coordinated with
µ [22–25]. Interestingly, the trends seem to be conserved between different organisms: commonly
with faster growth increase in the concentration of essential and conserved gene products such as
transcription and translation related proteins can be observed [22,26,27]. With this, downregulation of
less-essential proteins with functions such as signaling, external stimuli sensing, proteolysis, and motility
usually occurs. Similar trends can be observed even when changes in µ are caused by genome
modifications, which complicates the selection of best producing strains in conditions where µ cannot be
controlled (e.g., batch) [28]. Overflow metabolism is another example of µ-dependent rearrangement
of metabolism [29,30] that has been linked to reduced recombinant protein production [31]. This
is a phenomenon in which microorganisms growing faster than a certain threshold µ start using
fermentation—a much less efficient way than aerobic respiration for generating energy even in the
presence of oxygen.
Therefore, if processes are carried out in continuous cultures where µ can be fixed, the interpretation
and control of processes can be simplified as metabolic rearrangements due to changing µ can
be avoided.
3. µ-Dependent Recombinant Product Formation Kinetics
Chemostat cultures allow tight control over all growth conditions and the option to modify µ of
host cells by limiting the feeding rate of an essential growth substrate. For this reason, chemostats have
been widely used to determine the product formation kinetics—the relationship between µ and qp—in
many different organisms. These process characteristics can be directly compared between different
experimental setups as they are independent of process specific settings such as biomass density and
reactor volume. We summarize continuous cultures studies reporting product formation kinetics in
Table 1.
When comparing the maximal qp achieved in different µ-dependent studies, the highest qp values
have been reached with Escherichia coli. With the strong inducible T7 promoter, as high as 75% of
total protein production directed towards recombinant production has been reported [32]. Commonly
with this promoter, growth coupled increase in qp has been observed [32,33]. For other continuous
processes with E. coli, bell-shaped kinetics with a maximum qp most frequently achieved at medium µ
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values have been reported [34–37]. The decrease of qp above a threshold µ often co-occurred with high
acetate production, which probably limits the ability to reach a higher qp with faster growth [35,36].
Probably the most thorough µ-dependent recombinant process analysis has been carried out
using Pichia pastoris, recently summarized by Looser et al. [38]. In P. pastoris, most often two expression
systems are used: (1) methanol inducible AOX1 (alcohol oxidase (1)) and (2) constitutive glycolytic
GAP promoter (glyceraldehyde-3-phosphate dehydrogenase). For the methanol-inducible AOX
expression system, bell-shaped protein formation kinetics with a maximum qp near low growth
rates (µ < 0.1 h−1) have most commonly been observed [38–40], although growth coupled kinetics have
also been observed [41–43]. Possibly, these differences arise from the fact that methanol can been used
both as an inducer or the carbon source by P. pastoris. Overall, a low µ range has been demonstrated to
be optimal for AOX promoter-dependent protein expression. In S. cerevisiae, a galactose-dependent
expression system that is induced by galactose and repressed by glucose is often used. With this
promoter system used in galactose-based media, growth coupled qp has been observed [44]. In contrast,
glucose and galactose co-feeding resulted in a bell shaped qp kinetics, possibly because of increasing
inhibiting glucose concentrations at higher µ [45,46]. For the constitutive expression system relying on
glycolytic GAP promoter in P. pastoris, a growth coupled increase of qp with increasing µ has been
observed [27,47–49]. For GAP promoter-based systems highest qp values are commonly reported at
the maximum µ values above 0.15 h−1. Similar growth coupled product formation kinetics have been
reported for other yeast processes utilizing glycolytic promoters [50–52]. Transcriptome analysis of
glycolytic promoter-dependent protein expression in S. cerevisiae [51] and P. pastoris [27] was used for a
more detailed understanding of these processes. Both studies implied upregulation of stress response
and endoplasmic reticulum functions, and downregulation of proteasome activities play key roles in
the increased productivity with faster growth in these systems.
In contrast to most processes with yeast and bacteria, protein expression in Aspergillus niger
has often been carried out using chromosomal expression instead of plasmid-based systems [53–56].
Often, hosts with multiple copies of the target gene are used for stronger expression [53,55]. In most
cases, the product formation kinetics seem to be growth coupled and highest qp have been reached at
µ > 0.1 h−1 [53–56].
In summary, growth coupled product formation kinetics seems more common in continuous
cultures. This is probably one of the reasons why often satisfactory yields are reached using simple
batch cultures where µ is not restricted. Although empirical determination of optimal µ for each
new recombinant process should be carried out, some general trends can be estimated beforehand
depending on the host organism, promoter system and induction strategy.
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Table 1. µ-dependent product formation kinetics in continuous cultures. Abbreviations used: IFN: interferon; scFv: Single-Chain Variable Fragment Antibody;
GM-CSF: granulocyte- macrophage colony stimulating factor; VHH: variable domain of heavy chain antibody.
Organism Promoter Target Protein µ-Range (h−1) Optimal µ (qp,max) (h−1) qp,max (mg g−1 h−1) or (U mg−1 h−1) Kinetics Ref
E. coli Pbla β-lactamase 0.23–0.64 0.44 3.6 (U mg−1 h−1) bell shaped [34]
E. coli PL/cI857 Lymphokine 0.027–0.25 0.17 6.5 bell shaped [35]
E. coli Pbla β-lactamase 0.14–1 0.49 11 (U mg−1 h−1) bell shaped [36]
E. coli Plac Cyanase 0.05–0.93 0.15 8 (U mg−1 h−1) bell shaped [37]
E. coli T7 IFN-α 0.1–0.5 0.37 170 growth coupled [32]
E. coli T7 IFN-γ 0.1–0.3 0.3 75.00 growth coupled [33]
E. coli CP7 β-glucanase 0.1–0.5 0.15 14 (U mg−1 h−1) bell shaped [57]
P. pastoris AOX scFv 0.009–0.05 0.02 0.12 bell shaped [40]
P. pastoris a AOX scFv 0.007–0.05 0.04 0.004 linear [40]
P. pastoris AOX Trypsinogen 0.03–0.2 0.07 0.69 bell shaped [39]
P. pastoris AOX Chymotrypsinogen B 0.038–0.078 0.078 0.38 growth coupled [42]
P. pastoris AOX Antifreeze protein 0.01–0.09 0.09 0.065 growth coupled [43]
P. pastoris AOX Avidin 0.03–0.12 0.12 0.027 growth coupled [41]
P. pastoris GAP Serum Albumin 0.015–0.15 0.15 0.174 growth coupled [27]
P. pastoris GAP Fab 0.02–0.19 0.19 0.049 growth coupled [47]
P. pastoris GAP Fab 0.02–0.19 0.19 0.047 growth coupled [48]
P. pastoris GAP Fab 0.025–0.15 0.15 0.047 growth coupled [58]
P. pastoris GAP GM-CSF 0.02–0.2 0.2 0.5 growth coupled [49]
P. pastoris THI11 Serum albumin 0.05–0.15 0.15 0.18 growth coupled [50]
H. polymorpha MOX α-galactosidase 0.05–0.2 0.08 and 0.18 5.5 2 optima [45]
S. cerevisiae GAL7 α-galactosidase 0.05–0.225 0.17 4.5 bell shaped [45]
S. cerevisiae GAL7 VHH 0.033–0.172 0.172 3.87 growth coupled [44]
S. cerevisiae b GAL7 VHH 0.033–0.147 0.09 1.7 bell shaped [44]
S. cerevisiae GAL7 Cutinase 0.05–0.1 0.07 8 bell shaped [46]
S. cerevisiae TPI1 α-amylase 0.5–0.2 0.2 55 (µmoL mg−1 h−1) growth coupled [51]
S. cerevisiae TPI1 Insulin precursor 0.5–0.2 0.2 12 (µmoL mg−1 h−1) growth coupled [51]
K. lactis PGK Serum albumin 0.05–0.19 0.19 0.8 growth coupled [52]
K. lactis c PGK Serum albumin 0.05–0.12 0.12 0.225 growth coupled [52]
A. niger PglaA d Glycoamylase 0.06–0.14 0.14 12 growth coupled [53]
A. niger PglaA Glycoamylase 0.05–0.13 0.1 7 growth coupled [54]
A. niger PglaA d Glucoamylase 0.05–0.26 0.23 15 growth coupled [55]
A. niger Native e Acid phosphatases 0.04–0.13 0.13 7.5 (kU mg−1 h−1) growth coupled [56]
a Constant limited dissolved oxygen at 10%; b Nitrogen limited cultures; c High cell density culture with 60 g L−1 glucose; d 20 copies of glaA gene with its native chromosomal promoter; e
Several acid phosphatases expressed from their native promoters.
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4. Advanced Methods for µ-Dependent Recombinant Product Formation Kinetics
Applying chemostat cultivations for each new process development can be laborious and time
consuming. Chemostat starts as a batch culture, after which the culture is typically stabilized for
five bioreactor volume changes. This can take many days depending on the specified dilution
rate [59]. To increase throughput of continuous cultures, parallelization and miniaturization have
been used. For example, miniature chemostat systems have been developed for microbial physiology
studies [24,60,61]. Recently they have also been applied to optimize induction conditions in parallel
fermentations of recombinant protein expressing E. coli [62]. The miniature parallel chemostat was
further advanced to a cascade chemostat system where one reactor was used for biomass production
and the second reactor for the induction of recombinant protein expression [63]. Another multi-reactor
design was demonstrated by Erm et al., who used a single chemostat reactor to seed multiple
subsequent chemostats and study different recombinant expression induction strategies in E. coli [64].
These multistage cultivation experiments offer the advantage of faster process development due to
decreased time of steady inoculum preparation and separation of biomass growth from physiology
manipulation experiments.
Another improvement of the classical chemostat is the accelerostat cultivation method where the
dilution rate of culture (defines µ in steady state) is changed slowly enough for the cells to remain in a
state comparable with steady state [65]. This system has the benefit of reduced experimental time as
there is no need to stabilize culture for each new µ and has been shown to be highly similar to chemostat
cultivations [5]. The accelerostat method has been mainly used for microbial physiology studies for the
determination of metabolic rearrangements with changing µ (reviewed in [5]). Meier et al. applied the
accelerostat technique in the process development of a monoclonal antibody production in Hansenula
polymorpha and demonstrated highest space-time-yield near maximum µ of the organism [66]. Recently,
the accelerostat technique was used to determine the optimal µ for endo-polygalacturonase production
in S. cerevisiae. In the continuous culture, two optima were found, one at a lower µ below the
critical specific growth rate for aerobic overflow metabolism of ethanol, and the other at a higher µ.
Interestingly, in fed-batch cultivations, only the lower optimal µ was confirmed while the qp was low
at higher µ. [67]
5. Steady-State Bioprocess Optimization in Continuous Cultures
Besides µ-dependent product formation kinetics studies, continuous cultures have been used to
optimize many other process parameters. We summarized selected examples that demonstrate the
versatile uses of continuous cultures in recombinant process development in Table 2.
Controlled and constant environment provided by continuous cultures is an advantage that
can be effectively used to study the effect of growth conditions on plasmid stability. Brigidi et al.
compared several plasmids for α-amylase production in Bacillus stearothermophilus and identified a
system that could be maintained for more than 300 generations without significant plasmid loss [68].
Others have used continuous cultures to screen optimal growth conditions for plasmid maintenance in
non-selective medium and auxotrophic complementation systems [57,69,70]. Partow et al. used the
steady-state environment for a detailed comparison of plasmid-based promoter strengths and created
a novel expression system for use in glucose-based media [71].
Metabolic flux analysis has been widely used for identification of major intracellular pathways
and critical branch points in metabolic networks. Isotope incorporation analysis is considerably
simplified in steady-state conditions and therefore is most often carried out in chemostats. Fürch et al.
studied the metabolic link between glycolysis and the tricarboxylic acid (TCA) cycle in Bacillus
megaterium using 13C-labelled glucose and pyruvate [72]. They showed that a significant improvement
in recombinant hydrolase production could be achieved using pyruvate. Increase in both the adenosine
triphosphate (ATP) and nicotinamide adenine dinucleotide (NADPH) yields were determined on
pyruvate, providing a more optimal supply of both precursors as well as energy and reduction
equivalents for recombinant protein expression [72]. Pfeffer et al. developed a novel 34S labelling
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procedure for the flux measurements of a recombinant protein producing P. pastoris [73]. Using
carbon-limited continuous cultures, they discovered that from the total amount of protein produced
intracellularly, about 58% are degraded within the cell and only about 35% are secreted [73].
With the use of GAP promoters, often a strong positive correlation between qp and µ have been
reported (Table 1). Buchetics et al. used continuous cultures to analyze the correlation of cell cycle
and protein secretion rate of GAP-dependent expression of Fab in P. pastoris [48]. They showed that
qp was more correlated with cell cycle than µ, and based on the results, constructed strains with
customized cell cycle phase distribution. Resulting strains had increased qp at low µ, and increased
space-time-yield of the target proteins Fab and trypsinogen [48].
Besides the more advanced specific cases described above, there are many other process
parameters that have been optimized using steady-state continuous cultures: feed composition [74],
temperature [75,76], pH [52,55,77], dissolved oxygen [52], and inducer concentration [62]. Although
these process parameters can also be optimized in batch and fed-batch cultures, using continuous
cultures will avoid secondary effects arising from changing µ or biomass density.
Table 2. Main results of selected recombinant processes optimized in continuous cultures.
Organism Target Protein OptimisationCriteria Main Results Ref
B.
stearothermophilus α-amylase Plasmid stability
Several stable plasmids identified (up
to 200 generations tested). [68]
S. cerevisiae β-Galactosidase Promoter strengthcharacterisation
Novel expression vectors designed
with strong constitutive expression






Optimal metabolic flux distribution in








34S labelling identified 58%
degradation and 35% secretion of Fab.
[73]




Strain created with increased protein
secretion at low µ, improved
space-time-yield.
[48]
P. pastoris β-galactosidase Methanol: sorbitolco-feeding
0.45–0.75 C-moL/C-moL of methanol
fraction optimal for pAOX induction;
reduced oxygen demand.
[74]
E. coli Fab Optimaltemperature
30 ◦C favored over 33 ◦C and 37 ◦C
for Fab production without detriment
to biomass yield.
[76]
K. lactis Serum albumin Optimal pH (testedrange: 4–8) Highest qp reached at pH 6.5. [52]




Highest qp reached at lowest
dissolved oxygen conditions (5%)
tested.
[52]
E. coli mCherry Induction strategy
Dynamic increase of the inducer led
to an increase in the product
concentration of 21%
[62]
6. Continuous Manufacturing of Recombinant Proteins
Growing cells in continuous cultures results in a steady-state operation, which is easier to
characterize and understand, but it can also have economic benefits. Many growing industries
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have at one point made a switch from batch to continuous manufacturing and this has had a
tremendous effect on their efficiencies [9]. Several examples of continuous bioprocesses can be found,
including wastewater treatment, composting, biogas, ethanol, and single cell protein production [78,79].
Maintaining cells in a producing state for extended time periods is a major advantage that can lead to
high volumetric productivities in continuous bioprocesses. In case of processes with microorganisms,
the space-time-yields can be especially high due to their ability to grow very fast. Several other
benefits, such as lower setup and running costs, reduced equipment size, product quality and process
scalability, have been associated with continuous bioprocesses [8,9]. Continuous manufacturing in
smaller production vessels could also decrease the problems associated with process scale-up as pilot-
and production-scale processes can be carried out using more similar equipment. Even though high
efficiencies of continuous recombinant protein processes with different microorganisms can be found
in the scientific literature [39,63,80], their commercialization is limited. As adaptation is driven by
economics, the risks associated with continuous processes must be considered. Several issues possibly
affecting continuous manufacturing have been raised: challenges with long-term stability and sterility,
poor short-term flexibility due to long run times and genetic instability of cells to name a few [81]. Some
attempts have been made to create lower mutation rate hosts [82], but it is difficult to eliminate this risk
completely. Novel selection marker strategies [57], tunable expression [7], and bioprocess strategies [69]
have been used to mitigate the stability issues. Even if most of the hurdles can be overcome, the choice
between batch and continuous process finally depends on the longer-term objectives of the facilities
as large rearrangements or totally new systems are required. Possibly for these reasons, examples of
continuous recombinant protein productions are exclusively for the manufacturing of high demand
blockbuster biopharmaceuticals, for which semi-continuous perfusion technologies and mammalian
cell cultures are used [83]. The only known example of continuous industrial recombinant process
applying microorganisms dates back to the 1990s, when insulin was produced with S. cerevisiae, but
also in this case, process stability was problematic [84].
Besides the cultivation side, a production facility must also consider downstream operations
that need to be coupled with the upstream operations to maximize the benefits of a truly continuous
bioprocess. There are many recent developments in the direction of fully end-to-end continuous
recombinant protein production processes, which include downstream purification, cell lysis,
and protein refolding [85,86]. More recently, Kateja et al. developed an end-to-end integrated
continuous downstream process for a therapeutic protein expressed in E. coli as inclusion bodies [6].
Furthermore, Klutz et al. proposed a complete biofacility design based on a fully continuous
processing and single-use technology [87]. A recent patent on the integration of cultivation and
downstream chromatographic systems also demonstrates the growing industry interest in fully
continuous recombinant protein production processes [88].
7. Conclusions
Within this contribution, we focus on the application of continuous cultures for different aspects
of microbial recombinant protein production. Furthermore, we describe how methods of keeping cells
in constant environment using continuous cultures have been used to advance basic understanding of
recombinant cell physiology and for process development in microorganisms.
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